Daniel M. Anderson, MD, MPH
Principal Investigator, Metro-Minnesota Community Oncology Research Consortium
About

Affiliations/other offices held:聽Assistant Professor, Department of Hematology, Oncology and Transplantation, University of Minnesota.

Joined the Institute:听2003

Education and training:聽MD, University of Minnesota; residency in internal medicine, Hennepin County Medical Center; fellowship in hematology/oncology, University of Minnesota; MPH in epidemiology, University of Minnesota.

Overview/research interests:聽Dr. Anderson serves as the Principal Investigator for the Metro-Minnesota Community Oncology Research Consortium. Additionally, he is a co-chair of the Community Oncology Committee at the Alliance for Clinical Trials in Oncology. He became interested in working with people with cancer because of the unique relationships he has developed with them. He also enjoys the intellectual challenge of working with patients who have blood and clotting disorders. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research and Minnesota Society of Clinical Oncology.
Affiliation
positions
  • Principal Investigator, Metro-Minnesota Community Oncology Research Consortium, Cancer Research Center 2003 -
    • Publications While At 开云体育
    selected publications
    Journal Article
  • Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter cancer clinical trials. 
    Cancer. 2025
  • PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). 
    Journal of Clinical Oncology. 2024
  • Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer: final results from the POLARIS trial. 
    The oncologist. 2024
  • Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. 
    Commun Med (Lond). 2023
  • Validation of immunotherapy response score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit. 
    Cancer Res Commun. 2023
  • Organizational characteristics and smoking cessation support in community-based lung cancer screening programs. 
    Journal of the American College of Radiology. 2022
  • Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. 
    Lancet Oncology. 2021
  • Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. 
    European Journal of Cancer. 2021
  • Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples. 
    JCO precision oncology. 2021
  • A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: the MAESTRO study. 
    Cancer. 2020
  • Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. 
    Journal of Thrombosis and Haemostasis. 2020
  • Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. 
    Journal of Clinical Oncology. 2020
  • Sequencing ipilimumab immunotherapy before or after chemotherapy (nab-paclitaxel and bevacizumab) for the treatment of BRAFwt (BRAF wild-type) metastatic malignant melanoma: results of a study of Academic and Community Cancer Research United (ACCRU) RU261206I. 
    American Journal of Clinical Oncology. 2020
  • A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. 
    Cancer. 2019
  • Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. 
    Blood. 2018
  • The financial toll of cancer therapy: developing ways to help the patient. 
    Minn Physician. 2017
  • Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. 
    Annals of Oncology. 2016
  • A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. 
    American Journal of Hematology. 2015
  • North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. 
    Menopause (New York, N.Y.). 2015
  • NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. 
    Journal of Thoracic Oncology. 2014
  • N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. 
    Annals of Oncology. 2010
  • Impact of chemotherapy in women with metastatic breast cancer diagnosed 1990-2003. 
    Clinical Breast Cancer. 2007
    • Conference Poster
  • Psychological and spiritual well being of breast cancer survivors in a community-based cancer survivorship clinic [poster]
    2010
  • Statin use is associated with a reduced risk of colon cancer recurrence [poster]
    2008
  • Statin use is associated with a reduced risk of colon cancer recurrence [poster]
    2008
    • presentations
    Contact
    full name
  • Daniel M. Anderson, MD, MPH
    • located in facility
    Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration
    More Info